A phase II study of flavopiridol (alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer

Pancreatology

Volumn 9, Issue 4, 2009, Pages 404-409

  Carvajal, Richard D ^a   Tse, Archie ^a   Shah, Manish A ^a   Lefkowitz, Robert A ^a   Gonen, Mithat ^a   Gilman Rosen, Lisa ^a   Kortmansky, Jeremy ^b   Kelsen, David P ^a   Schwartz, Gary K ^a   O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Medical Oncology and Hematology ^*  (United States)

Author keywords

Cyclin dependent kinase inhibitors; Docetaxel; Flavopiridol; Gemcitabine refractory cancer; Pancreatic adenocarcinoma

Indexed keywords

ANTIEMETIC AGENT; DEXAMETHASONE; DOCETAXEL; FLAVOPIRIDOL; GEMCITABINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING; WEIGHT REDUCTION;

EID: 65649123880     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000187135     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Koorstra JB, Hustinx SR, Offerhaus GJ, Mai-tra A: Pancreatic carcinogenesis. Pancreatology 2008; 8:110-125.
3. Singh M, Maitra A: Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatolog y 2007; 7: 9-19.
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasyn-ski M, Parulekar W: Erlotinib plus gem-citabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966.
6. Cunningham D, Chau I, Stocken D, et al: Phase III randomised comparison of gem-citabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer (abstract PS11). Eur J Cancer 2005; 3: 4.
7. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kor-nek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25:2212- 2217.
8. Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, Clouet P, Le-becq A, Baille P, Lefresne-Soulas F, Blanc C, Armand JP: A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 36:1016 -1025.
9. Lenzi R, Yalcin S, Evans DB, Abbruzzese JL: Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 2002; 20: 464-472.
10. Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulias V: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 1999; 17:1779-1785.
11. Okada S, Sakata Y, Matsuno S, Kurihara M, Sasaki Y, Ohashi Y, Taguchi T: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 1999; 80: 438-443.
12. Attri J, Srinivasan R, Majumdar S, Radotra BD, Wig J: Alterations of tumor suppressor gene p16ink4a in pancreatic ductal carcinoma. BMC Gastroenterol 2005; 5:22.
13. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (mts1) gene in pancreatic adeno-carcinoma. Nat Genet 1994; 8:27-32.
14. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG: Abrogation of the rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57:3126-3130.
15. Ghaneh P, Greenhalf W, Humphreys M, Wilson D, Zumstein L, Lemoine NR, Neop-tolemos JP: Adenovirus-mediated transfer of p53 and p16(ink4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001; 8:199-208.
16. Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos J P, Costello E: 5-Fluorouracil or gemcitabine combined with adenoviral-mediated rein-troduction of P16ink4a greatly enhanced cy-totoxicity in panc-1 pancreatic adenocarci-noma cells. J Gene Med 2004; 6: 514 -525.
17. Kobayashi S, Shirasawa H, Sashiyama H, Kawahira H, Kaneko K, Asano T, Ochiai T: p16ink4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res 1999; 5:4182-4185.
18. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK: Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003; 2: 549-555.
19. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xeno-grafts. Clin Cancer Res 2001; 7:4209-4219.
20. Jung CP, Motwani MV, Schwartz GK: Flavo-piridol increases sensitization to gemcitabi-ne in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001; 7:2527-2536.
21. Motwani M, Delohery TM, Schwartz GK: Sequential dependent enhancement of cas-pase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999; 5: 1876 -1883.
22. Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK: Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13:5841- 5846.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
24. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
25. Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mul-cahy MF, Schilsky RL, Goldberg RM; Cancer and Leukemia Group B: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. ASCO Annual Meeting Proceedings (abstract). J Clin Oncol 2007; 25: 4508.
26. Schrag D, Archer L, Wang X, Romanus D, Mulcahy M, Goldberg R, Kindler H; Cancer and Leukemia Group B (CALGB): A pat-terns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gem-citabine therapy on Cancer and Leukemia Group B (CALGB) study 80303. ASCO Annual Meeting Proceedings (abstract). J Clin Oncol 2007; 25:4524.
27. Heinemann V, Quietzsch D, Gieseler F, Gon-nermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-3952.
28. Boeck S, Heinemann V: Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: 1178-1179; author reply 1179.
29. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS: Capecitabine plus erloti nib in gemcitabi-ne-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25:4787-4792.
30. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer 2006; 94:481-485.
31. Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, Wong R, Atkins J, Abruzzese J, Blanke C: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarci-noma [PC]: SWOG S0205 study. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25:LBA4509.